Literature DB >> 4040554

Cholecystokinin potentiates dopamine-mediated behaviors: evidence for modulation specific to a site of coexistence.

J N Crawley, J A Stivers, L K Blumstein, S M Paul.   

Abstract

Cholecystokinin coexists with dopamine in mesolimbic neurons in mammalian brain. When injected directly into the nucleus accumbens, cholecystokinin (CCK) potentiated dopamine (DA)-induced hyperlocomotion and apomorphine-induced stereotypy. These effects were not mimicked by nonsulfated CCK, but were blocked by proglumide, a putative CCK antagonist, as well as by antisera raised against sulfated CCK. CCK alone had no effect on locomotion or sterotypy, indicating that this peptide acts primarily as a modulator of DA-mediated behaviors in the mesolimbic pathway. In addition, CCK did not potentiate DA-induced hyperlocomotion or apomorphine-induced stereotypy when injected into the caudate nucleus, where CCK and DA are localized in separate neurons in rats. Facilitation of DA-mediated behaviors by CCK may represent a functional interaction specific to the neuromodulator-neurotransmitter coexistence phenomenon.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4040554      PMCID: PMC6565292     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  11 in total

1.  Differential effects of proglumide on mesolimbic and nigrostriatal dopamine function.

Authors:  J G Csernansky; S Glick; J Mellentin
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

2.  CCK-8 injected into the nucleus accumbens attenuates the supersensitive locomotor response to apomorphine in 6-OHDA and chronic-neuroleptic treated rats.

Authors:  F Weiss; A Ettenberg; G F Koob
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

3.  Sexual behavior induction of c-Fos in the nucleus accumbens and amphetamine-stimulated locomotor activity are sensitized by previous sexual experience in female Syrian hamsters.

Authors:  K C Bradley; R L Meisel
Journal:  J Neurosci       Date:  2001-03-15       Impact factor: 6.167

4.  Galanin antagonizes acetylcholine on a memory task in basal forebrain-lesioned rats.

Authors:  J Mastropaolo; N S Nadi; N L Ostrowski; J N Crawley
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

5.  Neurotensin and cholecystokinin coexistence within neurons of the ventral mesencephalon: projections to forebrain.

Authors:  K B Seroogy; A Mehta; J H Fallon
Journal:  Exp Brain Res       Date:  1987       Impact factor: 1.972

6.  Cholecystokinin and tyrosine hydroxylase messenger RNAs in neurons of rat mesencephalon: peptide/monoamine coexistence studies using in situ hybridization combined with immunocytochemistry.

Authors:  K Seroogy; M Schalling; S Brené; A Dagerlind; S Y Chai; T Hökfelt; H Persson; M Brownstein; R Huan; J Dixon
Journal:  Exp Brain Res       Date:  1989       Impact factor: 1.972

7.  Cholecystokinin and psychiatric disorders : role in aetiology and potential of receptor antagonists in therapy.

Authors:  J Shlik; E Vasar; J Bradwejn
Journal:  CNS Drugs       Date:  1997-08       Impact factor: 5.749

8.  Differential involvement of CCK-A and CCK-B receptors in the regulation of locomotor activity in the mouse.

Authors:  E Vasar; J Harro; A Lang; A Pôld; A Soosaar
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

9.  Total synthesis, purification, and characterization of human [Phe(p-CH2SO 3Na)52, Nle32,53,56, Nal55]-CCK20-58, [Tyr52, Nle32,53,56, Nal55]-CCK-58, and [Phe(p-CH2SO3Na)52, Nle32,53,56, Nal55]-CCK-58.

Authors:  M T Miranda; A G Craig; C Miller; R A Liddle; J E Rivier
Journal:  J Protein Chem       Date:  1993-10

10.  Tyrosine hydroxylase and cholecystokinin mRNA levels in the substantia nigra, ventral tegmental area, and locus ceruleus are unaffected by acute and chronic haloperidol administration.

Authors:  S L Cottingham; D Pickar; T K Shimotake; P Montpied; S M Paul; J N Crawley
Journal:  Cell Mol Neurobiol       Date:  1990-03       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.